2017 European guideline for the management of pelvic inflammatory disease

Jonathan Ross, Secondo Guaschino, Marco Cusini, Jorgen Jensen

Research output: Contribution to journalArticle

  • 2 Citations

Abstract

The European guideline for the management of pelvic inflammatory disease includes evidence-based advice on the investigation and treatment of pelvic inflammatory disease (PID). It has been updated to acknowledge the role of Mycoplasma genitalium as an important cause of PID with testing now recommended for women presenting with possible PID and for the male partners of women with confirmed M. genitalium infection. Recent evidence suggests that serious adverse events are uncommon when using moxifloxacin and its use is now recommended as a first-line therapy, especially in those women with M. genitalium PID. The potential utility of MRI scanning of the pelvis in excluding differential diagnoses has been highlighted. The use of doxycycline is now suggested as empirical treatment for male partners of women with PID to reduce exposure to macrolide antibiotics, which has been associated with increased resistance in M. genitalium.

LanguageEnglish
Pages108-114
Number of pages7
JournalInternational Journal of STD and AIDS
Volume29
Issue number2
DOIs
Publication statusPublished - Feb 1 2018

Fingerprint

Pelvic Inflammatory Disease
Mycoplasma genitalium
Guidelines
Mycoplasma Infections
Doxycycline
Macrolides
Pelvis
Differential Diagnosis
Therapeutics
Anti-Bacterial Agents

Keywords

  • antibiotics
  • guideline
  • Pelvic infection
  • pelvic inflammatory disease
  • salpingitis
  • treatment

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

2017 European guideline for the management of pelvic inflammatory disease. / Ross, Jonathan; Guaschino, Secondo; Cusini, Marco; Jensen, Jorgen.

In: International Journal of STD and AIDS, Vol. 29, No. 2, 01.02.2018, p. 108-114.

Research output: Contribution to journalArticle

Ross, Jonathan ; Guaschino, Secondo ; Cusini, Marco ; Jensen, Jorgen. / 2017 European guideline for the management of pelvic inflammatory disease. In: International Journal of STD and AIDS. 2018 ; Vol. 29, No. 2. pp. 108-114.
@article{d588e0459a684754af60ae5187ddf469,
title = "2017 European guideline for the management of pelvic inflammatory disease",
abstract = "The European guideline for the management of pelvic inflammatory disease includes evidence-based advice on the investigation and treatment of pelvic inflammatory disease (PID). It has been updated to acknowledge the role of Mycoplasma genitalium as an important cause of PID with testing now recommended for women presenting with possible PID and for the male partners of women with confirmed M. genitalium infection. Recent evidence suggests that serious adverse events are uncommon when using moxifloxacin and its use is now recommended as a first-line therapy, especially in those women with M. genitalium PID. The potential utility of MRI scanning of the pelvis in excluding differential diagnoses has been highlighted. The use of doxycycline is now suggested as empirical treatment for male partners of women with PID to reduce exposure to macrolide antibiotics, which has been associated with increased resistance in M. genitalium.",
keywords = "antibiotics, guideline, Pelvic infection, pelvic inflammatory disease, salpingitis, treatment",
author = "Jonathan Ross and Secondo Guaschino and Marco Cusini and Jorgen Jensen",
year = "2018",
month = "2",
day = "1",
doi = "10.1177/0956462417744099",
language = "English",
volume = "29",
pages = "108--114",
journal = "International Journal of STD and AIDS",
issn = "0956-4624",
publisher = "SAGE Publications Ltd",
number = "2",

}

TY - JOUR

T1 - 2017 European guideline for the management of pelvic inflammatory disease

AU - Ross, Jonathan

AU - Guaschino, Secondo

AU - Cusini, Marco

AU - Jensen, Jorgen

PY - 2018/2/1

Y1 - 2018/2/1

N2 - The European guideline for the management of pelvic inflammatory disease includes evidence-based advice on the investigation and treatment of pelvic inflammatory disease (PID). It has been updated to acknowledge the role of Mycoplasma genitalium as an important cause of PID with testing now recommended for women presenting with possible PID and for the male partners of women with confirmed M. genitalium infection. Recent evidence suggests that serious adverse events are uncommon when using moxifloxacin and its use is now recommended as a first-line therapy, especially in those women with M. genitalium PID. The potential utility of MRI scanning of the pelvis in excluding differential diagnoses has been highlighted. The use of doxycycline is now suggested as empirical treatment for male partners of women with PID to reduce exposure to macrolide antibiotics, which has been associated with increased resistance in M. genitalium.

AB - The European guideline for the management of pelvic inflammatory disease includes evidence-based advice on the investigation and treatment of pelvic inflammatory disease (PID). It has been updated to acknowledge the role of Mycoplasma genitalium as an important cause of PID with testing now recommended for women presenting with possible PID and for the male partners of women with confirmed M. genitalium infection. Recent evidence suggests that serious adverse events are uncommon when using moxifloxacin and its use is now recommended as a first-line therapy, especially in those women with M. genitalium PID. The potential utility of MRI scanning of the pelvis in excluding differential diagnoses has been highlighted. The use of doxycycline is now suggested as empirical treatment for male partners of women with PID to reduce exposure to macrolide antibiotics, which has been associated with increased resistance in M. genitalium.

KW - antibiotics

KW - guideline

KW - Pelvic infection

KW - pelvic inflammatory disease

KW - salpingitis

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85040443519&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040443519&partnerID=8YFLogxK

U2 - 10.1177/0956462417744099

DO - 10.1177/0956462417744099

M3 - Article

VL - 29

SP - 108

EP - 114

JO - International Journal of STD and AIDS

T2 - International Journal of STD and AIDS

JF - International Journal of STD and AIDS

SN - 0956-4624

IS - 2

ER -